-
1
Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) like colitis and myocarditis, impacting quality of life and treatment outcomes.
-
2
Single-cell RNA sequencing (scRNA-seq) provides high-resolution profiling of immune cell heterogeneity, aiding in understanding the mechanisms of irAEs.
-
3
ICI-associated colitis incidence varies by treatment regimen, with anti-CTLA-4 therapies showing a higher risk compared to anti-PD-1/PD-L1 therapies.
-
4
Symptoms of ICI-induced colitis typically appear 4 to 8 weeks after treatment initiation, with diarrhea being the predominant symptom.
-
5
Diagnosis of ICI-associated colitis involves clinical assessment, laboratory evaluations, and colonoscopic examination to identify mucosal inflammation.
